跳至主要内容
临床试验/KCT0005982
KCT0005982尚未招募未知

Effect of Effect of Combined Administration of Pilocarpine and Herbal medicine (Baekhogainsa m-Tang Ext. Granule) on frequent intractable dry mouth: A randomized, open-label, parallel, m ulti-center trial

Kyung Hee University Hospital0 个研究点目标入组 108 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
108

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 80(Year)(—)
性别
All

入选标准

  • 1. One or more of the following:
  • History of radiation therapy in the head and neck area
  • Diagnosed as Sjogren's syndrome (the following two conditions are met)
  • -Anti-Ro/SSA test positive
  • -Saliva flow rate (Unstimulated) = 0.1mL/min
  • 2. Less than 0.25 ml/min in unstimulated test among salivary flow test (SFR)
  • 3. At least 4 points on the Visual Analog Scale for dry mouth for the last 1 month
  • 4. Over 19 years old
  • 5. Those who agreed in writing to participate in clinical trials

排除标准

  • Exclusion criteria
  • 1. Those with the following diseases or history
  • heart failure
  • Patients with systolic blood pressure of 160 mmHg or higher or diastolic blood pressure of 100 mmHg or higher despite treatment with hypertension drugs
  • Patients with or have a history of bronchial asthma
  • arrhythmia
  • Coronary artery (cardiac artery) disease
  • Asthma, chronic bronchitis or chronic obstructive pulmonary disease
  • Congenital amino acid metabolism abnormality
  • There is a risk of intersex coma or intersex coma
  • People with narrow angle glaucoma, peripheral retinopathy, iritis, and other eye diseases where the use of pilocarpine is contraindicated.
  • 2. Those taking anticholinergics, antidepressants, ACE inhibitors, ß-adrenergic antagonists, diuretics, anticoagulants, antihistamines, narcotic analgesics, antiplatelet drugs, mineralocorticoids, and digitalis drugs (cardiac drugs)
  • 3. A person whose blood test results conducted within 7 days prior to the start date of administration of the investigational drug meet the following criteria:
  • Hemoglobin less than 8.0g/dL
  • AST (GOT) and ALT (GPT) exceeded 3.0 times the upper limit of the laboratory standard
  • Total bilirubin exceeds 2.0 times the upper limit of the laboratory standard
  • Creatinine exceeds the upper limit of 1.5 times the laboratory standard or the creatinine clearance (actual value or estimated by Cockcroft/Gault formula) is less than 60 mL/min.
  • 4. Pregnant or breastfeeding persons, persons who have not used appropriate contraception (oral, injection, infusion or hormonal contraception methods, intrauterine devices and blocking methods)
  • 5. A person who disagrees with contraception for 4 weeks after the end of administration of the test drug if the male investigator's proper contraception method is not used (both male and female)
  • 6. Galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  • 7. Those who have difficulty administering clinical trial drugs orally
  • 8. Those who showed clinically significant hypersensitivity to Baekho Gaginsam-tang and its major components
  • 9. Those who showed a clinically significant hypersensitivity reaction to pilocarpine
  • 10. A person who is judged to be unsuitable for participation in clinical trials based on the judgment of the researcher due to the screening test results and other reasons
  • 11. Those with cognitive decline or unable to read or write

研究者

发起方
Kyung Hee University Hospital

相似试验